Diffuse Bone Marrow Uptake on Whole-Body F-18 Fluorodeoxyglucose Positron Emission Tomography in a Patient Taking Recombinant Erythropoietin

Clinical Nuclear Medicine

Volumn 29, Issue 3, 2004, Pages 161-163

  Blodgett, Todd M ^a,b   Ames, Jennifer T ^a   Torok, Frank S ^a   McCook, Barry M ^a   Meltzer, Carolyn C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Epogen; Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; ARTIFACT; BONE CANCER; BONE MARROW; BONE MARROW METASTASIS; CANCER DIAGNOSIS; CASE REPORT; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG UPTAKE; HUMAN; MALE; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY SCINTISCANNING;

AGED; ARTIFACTS; BONE MARROW; BONE MARROW NEOPLASMS; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; ERYTHROPOIETIN, RECOMBINANT; FLUORODEOXYGLUCOSE F18; HUMANS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 1542377497     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000115654.90324.02     Document Type: Article

References (20)

1. Warburg O. The metabolism of tumors. In: Smith RR, ed. 1931:129-169.
2. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378.
3. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19: 61-77; quiz 150-151.
4. Sugawara Y. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173-180.
5. Yao WJ, Hoh CK, Hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794-799.
6. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91: 3340-3346.
7. Hung GU, Tan TS, Kao CH, et al. Multiple skeletal metastases of Ewing's sarcoma demonstrated on FDG-PET and compared with bone and gallium scans. Kaohsiung J Med Sci. 2000;16:315-318.
8. Lewanski CR, Kaplan GR, Potter J, et al. Bone marrow involvement in breast cancer detected by positron emission tomography. J R Soc Med. 1999;92:193-195.
9. Petren-Mallmin M. Clinical and experimental imaging of breast cancer metastases in the spine. Acta Radiol Suppl. 1994;391:1-23.
10. Taaleb K, Kaiser KP, Wieler H. Elevated uptake of F-18 FDG in PET scans in nonmalignant disease. Clin Nucl Med. 2000;25:939-940.
11. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol. 1997;169:1675-1680.
12. Cabrera Villegas A CFA, Martin Urreta JC. [Post-radiation pneumonitis in a case of Hodgkin's lymphoma assessed with PET-FDG by residual mediastinal mass.] Rev Esp Med Nucl. 2000;19:288-292.
13. Zhuang H. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med. 2000; 25:281-284.
14. Meyer M, Gast T, Raja S, et al. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med. 1994;19:13-14.
15. Gundlapalli S, Ojha B, Mountz JM. Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med. 2002;27:140-141.
16. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999;20:13-20.
17. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991;32:1508-1512.
18. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93-98.
19. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173-180.
20. Yao WJ, Hoh CK, Hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794-799.